Alderley Park, 31 May 2024 – BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next  generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst eliminating treatment-related toxicities, today announces its audited results for the twelve months ended 31 December 2023. The Annual Report and Accounts for the year ended  31 December 2023, will be posted to shareholders in due course together with the notice of the 2024  Annual General Meeting.

Please Read PDF RNS HERE